272 related articles for article (PubMed ID: 17888101)
1. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
Thompson D; Taylor DC; Montoya EL; Winer EP; Jones SE; Weinstein MC
Value Health; 2007; 10(5):367-76. PubMed ID: 17888101
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
Risebrough NA; Verma S; Trudeau M; Mittmann N
Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
[TBL] [Abstract][Full Text] [Related]
3. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden.
Lundkvist J; Wilking N; Holmberg S; Jönsson L
Breast Cancer Res Treat; 2007 May; 102(3):289-99. PubMed ID: 17033927
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Skedgel C; Rayson D; Dewar R; Younis T
Breast Cancer Res Treat; 2007 Mar; 101(3):325-33. PubMed ID: 16897433
[TBL] [Abstract][Full Text] [Related]
7. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Coombes RC; Kilburn LS; Snowdon CF; Paridaens R; Coleman RE; Jones SE; Jassem J; Van de Velde CJ; Delozier T; Alvarez I; Del Mastro L; Ortmann O; Diedrich K; Coates AS; Bajetta E; Holmberg SB; Dodwell D; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Forbes J; Castiglione M; Stuart N; Stewart A; Fallowfield LJ; Bertelli G; Hall E; Bogle RG; Carpentieri M; Colajori E; Subar M; Ireland E; Bliss JM;
Lancet; 2007 Feb; 369(9561):559-70. PubMed ID: 17307102
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
9. To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
Iddon J; Bundred NJ
Expert Rev Anticancer Ther; 2008 Jan; 8(1):9-13. PubMed ID: 18095878
[TBL] [Abstract][Full Text] [Related]
10. Exemestane: a review of its use in postmenopausal women with breast cancer.
Deeks ED; Scott LJ
Drugs; 2009; 69(7):889-918. PubMed ID: 19441873
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Skedgel C; Rayson D; Dewar R; Younis T
Breast; 2007 Jun; 16(3):252-61. PubMed ID: 17207623
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
[TBL] [Abstract][Full Text] [Related]
14. Intergroup Exemestane Study mature analysis: overall survival data.
Jassem J;
Anticancer Drugs; 2008 Feb; 19 Suppl 1():S3-7. PubMed ID: 18340242
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
16. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
Erman A; Nugent A; Amir E; Coyte PC
Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
[TBL] [Abstract][Full Text] [Related]
18. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.
Bliss JM; Kilburn LS; Coleman RE; Forbes JF; Coates AS; Jones SE; Jassem J; Delozier T; Andersen J; Paridaens R; van de Velde CJ; Lønning PE; Morden J; Reise J; Cisar L; Menschik T; Coombes RC
J Clin Oncol; 2012 Mar; 30(7):709-17. PubMed ID: 22042946
[TBL] [Abstract][Full Text] [Related]
19. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
20. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
